News Image

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Provided By PR Newswire

Last update: Apr 30, 2025

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –

Read more at prnewswire.com

IMMUNIC INC

NASDAQ:IMUX (7/24/2025, 4:11:00 PM)

After market: 1.04 -0.03 (-2.8%)

1.07

+0.07 (+7%)



Find more stocks in the Stock Screener

Follow ChartMill for more